Shots:

• The P-II IXPLORE study involves assessing vilobelimab (400/800mg- q2w) + SOC vs PBO + SOC in 19 patients with ANCA associated vasculitis or AAV in the US
• The therapy is safe and well-tolerated in combination with SoC- clinical response & remission for each treatment group @16wks. was measured as 2EPs and showed 50% reduction in BVAS- patients in higher dose (800mg) showed BVAS (17.5mean / 16.5median)- while 400mg dose showed (13.1 mean / 12.0 median) vs (13.8mean / 13.5median) with SOC group
• The results further support the continued study of vilobelimab for the treatment of AAV. Part 1 & 2 of the P-II IXCHANGE trial are fully enrolled in the EU- results are expected in the end of 2021

  Ref: InflaRx | Image: InflaRx